ESR1 Innovations Transforming Breast Cancer Treatment
Advancements in cancer research have spotlighted ESR1 mutations and fusions as pivotal factors in breast cancer’s endocrine resistance. New therapies, including Selective Estrogen Receptor Degraders, offer promising solutions alongside molecular testing for personalized treatments. Exploring the impact of these innovations yields critical insights into overcoming treatment challenges and enhancing outcomes for breast cancer patients. Promising […]
3 minute read